Adelmidrol, another PPARα, and PPAR-α/γ dual agonist reduce MMP-1, TNF-α, AST, ALT, TAG, while increasing HDL and adiponectin levels as well as improving histopathological changes in HFD-induced NASH mice [213]. Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.